Cargando…

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has demonstrated efficacy in treating subependymal giant cell astrocytomas (SEGAs) and other manifestations of tuberous sclerosis complex (TSC). However, long-term use of mTOR inhibitors might be necessary. This analysis explo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franz, David N., Belousova, Elena, Sparagana, Steven, Bebin, E. Martina, Frost, Michael D., Kuperman, Rachel, Witt, Olaf, Kohrman, Michael H., Flamini, J. Robert, Wu, Joyce Y., Curatolo, Paolo, de Vries, Petrus J., Berkowitz, Noah, Niolat, Julie, Jóźwiak, Sergiusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924870/ https://www.ncbi.nlm.nih.gov/pubmed/27351628 http://dx.doi.org/10.1371/journal.pone.0158476

Ejemplares similares

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study
por: Bissler, John J., et al.
Publicado: (2017)

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2
por: Bissler, John J, et al.
Publicado: (2019)

Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis – Final Results From the EMINENTS Study
por: Bobeff, Katarzyna, et al.
Publicado: (2021)

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex
por: Sparagana, Steven, et al.
Publicado: (2017)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Editorial: Tuberous Sclerosis Complex – Diagnosis and Management
por: Jozwiak, Sergiusz, et al.
Publicado: (2021)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
por: Fogarasi, Andras, et al.
Publicado: (2016)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications
por: Trelinska, Joanna, et al.
Publicado: (2016)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas
por: Kingswood, J. Chris, et al.
Publicado: (2020)

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis
por: Franz, David N., et al.
Publicado: (2015)

Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness
por: Kingswood, J Chris, et al.
Publicado: (2019)

Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND)
por: de Vries, Petrus J., et al.
Publicado: (2021)

Risk Factors Associated with Refractory Epilepsy in Patients with Tuberous Sclerosis Complex: A Systematic Review
por: Miszewska, Dominika, et al.
Publicado: (2021)

Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA)
por: Sauter, Matthias, et al.
Publicado: (2021)

Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age—A Bicenter Retrospective Study
por: Śmiałek, Dominika, et al.
Publicado: (2023)

Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study
por: Nabbout, Rima, et al.
Publicado: (2018)

Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
por: Jansen, Anna C., et al.
Publicado: (2019)

Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review
por: Sugalska, Monika, et al.
Publicado: (2021)

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
por: Śmiałek, Dominika, et al.
Publicado: (2023)

Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results
por: Ruiz-Falcó Rojas, María Luz, et al.
Publicado: (2022)

The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial
por: Randell, Elizabeth, et al.
Publicado: (2016)

Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study
por: Jansen, Anna C., et al.
Publicado: (2020)

TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex
por: Kingswood, John C, et al.
Publicado: (2014)

Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry
por: Nabbout, Rima, et al.
Publicado: (2021)

TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
por: Kingswood, John C., et al.
Publicado: (2017)

Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry
por: Marques, Ruben, et al.
Publicado: (2019)

The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
por: Marques, Ruben, et al.
Publicado: (2019)

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()
por: Gipson, Tanjala T., et al.
Publicado: (2013)

Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study
por: Jansen, Anna C., et al.
Publicado: (2019)

Early Vascular Aging in Children With Tuberous Sclerosis Complex
por: Skrzypczyk, Piotr, et al.
Publicado: (2021)

Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex
por: Kotulska, Katarzyna, et al.
Publicado: (2014)

Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2
por: Kwiatkowski, David J, et al.
Publicado: (2015)

Tuberous Sclerosis Complex Patients’ Needs and Difficulties—Results of TAND Questionnaire Analysis in Polish Adult Population
por: Marcinkowska, Anna B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_smnstr9qsgof3uh8on39oa06p1